<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04269408</url>
  </required_header>
  <id_info>
    <org_study_id>BIT-002</org_study_id>
    <secondary_id>2017-005159-10</secondary_id>
    <nct_id>NCT04269408</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Study of NicaPlant® in Aneurysmal Subarachnoid Haemorrhage Patients Undergoing Aneurysm Clipping</brief_title>
  <official_title>A Phase IIb: Randomised, Single-Blind, Safety, Tolerability, Efficacy and Pharmacokinetic Study of NicaPlant® in Aneurysmal Subarachnoid Haemorrhage Patients Undergoing Aneurysm Clipping</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BIT Pharma GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NeuroScios GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Data Magik Limited</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pharm-Analyt Labor GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>BIT Pharma GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study of NicaPlant® is conducted in patients who have a subarachnoid haemorrhage.
      Patients will be randomized in two treatment groups. Both groups will receive the standard of
      care and the investigational group will receive in addition NicaPlant®. NicaPlant® is tested
      to reduce the long-term complications of aneurysmal subarachnoid haemorrhage (aSAH).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a safety, tolerability, efficacy and pharmacokinetic study of NicaPlant® in
      subarachnoid haemorrhage patients involving two treatment groups. Both treatment groups will
      receive standard of care and patients randomised to the investigational group will receive in
      addition NicaPlant® .

      NicaPlant® is a nicardipine modified-release formulation. It is presented in the form of a
      rod-shaped implant with a 4 mg nicardipine load. Following aneurysm clip ligation, 10
      NicaPlant® implants will be placed into the basal cisterns in direct contact with the exposed
      cerebral blood vessel walls.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 5, 2020</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
    <masking_description>The clinical trial is defined as a single-blind study. For ethical reasons, no placebo implants will be used and therefore the surgeon cannot be blinded. All investigators/surgeons who have not been involved in the operation of a patient will remain blinded for this particular patient.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of moderate to severe cerebral angiographic vasospasm assessed by digital subtraction angiography</measure>
    <time_frame>day 8 ± 1 after aneurysm rupture</time_frame>
    <description>Fishers Exact test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety by adverse event recording</measure>
    <time_frame>trough study completion, an average of 2 years</time_frame>
    <description>Descriptive summary</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of new cerebral infarcts on computer tomography (CT) of the brain versus post-intervention CT scan</measure>
    <time_frame>up to day 14 ± 1 after aneurysm rupture</time_frame>
    <description>Fishers exact test</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of vasospasm-related morbidity/mortality</measure>
    <time_frame>within 21 days post aneurysm rupture</time_frame>
    <description>Fishers exact test</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetic profile of NicaPlant® in plasma</measure>
    <time_frame>within 21 days post aneurysm rupture or within hospitalisation if shorter</time_frame>
    <description>AUC for multiple plasma samples</description>
  </other_outcome>
  <other_outcome>
    <measure>Nicardipine levels in cerebrospinal fluid (CSF) (only in patients provided with an external ventricular drain (EVD) at time of CSF removal for medical reasons)</measure>
    <time_frame>within 21 days post aneurysm rupture or within hospitalisation if shorter</time_frame>
    <description>Average concentration (Cav) for single CSF samples if sufficient CSF data is obtained.</description>
  </other_outcome>
  <other_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>week 52 ± 2 after aneurysm rupture</time_frame>
    <description>ANOVA</description>
  </other_outcome>
  <other_outcome>
    <measure>Modified Rankin Scale</measure>
    <time_frame>week 12 ± 1 after aneurysm rupture</time_frame>
    <description>Cochran-Mantel-Haenzel (CMH) test (with modified ridits)
minimum value: 0, maximum value: 6, higher scores mean a worse outcome</description>
  </other_outcome>
  <other_outcome>
    <measure>Modified Rankin Scale</measure>
    <time_frame>week 52 ± 2 after aneurysm rupture</time_frame>
    <description>Cochran-Mantel-Haenzel (CMH) test (with modified ridits)
minimum value: 0, maximum value: 6, higher scores mean a worse outcome</description>
  </other_outcome>
  <other_outcome>
    <measure>Glasgow Outcome Scale Extended</measure>
    <time_frame>week 12 ± 1 after aneurysm rupture</time_frame>
    <description>Cochran-Mantel-Haenzel (CMH) test (with modified ridits)
minimum value: 1, maximum value: 8, higher scores mean a better outcome</description>
  </other_outcome>
  <other_outcome>
    <measure>Glasgow Outcome Scale Extended</measure>
    <time_frame>week 52 ± 2 after aneurysm rupture</time_frame>
    <description>Cochran-Mantel-Haenzel (CMH) test (with modified ridits)
minimum value: 1, maximum value: 8, higher scores mean a better outcome</description>
  </other_outcome>
  <other_outcome>
    <measure>Montreal Cognitive Assessment</measure>
    <time_frame>week 12 ± 1 after aneurysm rupture</time_frame>
    <description>ANOVA
minimum value: 0, maximum value: 30, higher scores mean a better outcome</description>
  </other_outcome>
  <other_outcome>
    <measure>Montreal Cognitive Assessment</measure>
    <time_frame>week 52 ± 2 after aneurysm rupture</time_frame>
    <description>ANOVA
minimum value: 0, maximum value: 30, higher scores mean a better outcome</description>
  </other_outcome>
  <other_outcome>
    <measure>EQ-5D-5L</measure>
    <time_frame>week 12 ± 1 after aneurysm rupture</time_frame>
    <description>ANOVA</description>
  </other_outcome>
  <other_outcome>
    <measure>EQ-5D-5L</measure>
    <time_frame>week 52 ± 2 after aneurysm rupture</time_frame>
    <description>ANOVA</description>
  </other_outcome>
  <other_outcome>
    <measure>SF36</measure>
    <time_frame>week 12 ± 1 after aneurysm rupture</time_frame>
    <description>ANOVA</description>
  </other_outcome>
  <other_outcome>
    <measure>SF36</measure>
    <time_frame>week 52 ± 2 after aneurysm rupture</time_frame>
    <description>ANOVA</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Aneurysmal Subarachnoid Hemorrhage</condition>
  <arm_group>
    <arm_group_label>NicaPlant®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 NicaPlant® implants (total 40 mg nicardipine) will be placed after clip ligation into the basal cisterns in direct contact with the exposed cerebral blood vessel walls.
In addition patients will receive standard of care for aneurysmal subarachnoid haemorrhage patients according to the treatment guidelines.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Standard of care for aneurysmal subarachnoid haemorrhage patients according to the treatment guidelines.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicardipine</intervention_name>
    <description>10 NicaPlant® implants releasing 4 mg nicardipine each.</description>
    <arm_group_label>NicaPlant®</arm_group_label>
    <other_name>NicaPlant®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of care</intervention_name>
    <description>Both arms receive the usual standard of care.</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>NicaPlant®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent obtained according to the Country regulation.

          -  Male or female patients aged 18 to 75 years (inclusive).

          -  World Federation of Neurological Surgeons (WFNS) grade III-IV.

          -  Ruptured saccular aneurysm, confirmed by angiography.

          -  Onset of aSAH clinical symptoms within the preceding 48 hours.

          -  Treatment of aneurysm via surgical clip ligation within 72 hours of aSAH is
             achievable.

          -  Female patients of child-bearing potential must have a negative pregnancy test (urine
             or serum) at screening and must agree to use adequate birth control up to 12 weeks
             after implantation of the study drug. Female patients are considered to be not of
             child-bearing potential if they have a history of tubal ligation or hysterectomy or
             are post-menopausal with a minimum of 2 years without a natural menstrual cycle. Male
             patients must agree to use adequate birth control up to 12 weeks after implantation of
             the study drug.

        Exclusion Criteria:

          -  SAH due to other causes (e.g. trauma, fusiform or mycotic aneurysm).

          -  World Federation of Neurosurgery (WFNS) grade I, II and V patients.

          -  Pregnant or Lactating Women.

          -  Intraventricular or intracerebral blood, in the absence of subarachnoid blood.

          -  Treatment of aneurysm via endovascular embolisation.

          -  Presence of moderate or severe vasospasm on screening angiography.

          -  Any known or CT /MRI evidence of previous major cerebral damage

          -  Evidence of a cerebral infarction with neurological deficit on pre-treatment CT/MRI.

          -  History of malignant disease (except for non-melanoma skin cancer) within the previous
             5 years or any history of malignant brain tumours or brain metastasis.

          -  Patients who have received an investigational product or participated in another
             interventional clinical study within 30 days prior to randomisation.

          -  Patients with known allergy for Poly(D,L-lactide-co-glycolide) (PLGA) or nicardipine.

          -  Major complication during aneurysm repair such as, but not limited to, massive
             intraoperative haemorrhage, brain swelling, or inability to secure the ruptured
             aneurysm.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claudius Thomé, Prof.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinik Innsbruck, Universitätsklinik für Neurochirurgie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tiziana Adage, Dr.</last_name>
    <phone>+43 (0)664 3972384</phone>
    <email>tiziana.adage@bit-pharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universitätsklinik Innsbruck, Universitätsklinik für Neurochirurgie</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudius Thomé, Prof.Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Claudius Thomé, Prof.Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian Freyschlag, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Johannes Kerschbaumer, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kepler Universitätsklinikum, Universitätsklinik für Neurochirurgie</name>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Gruber, Prof.Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Andreas Gruber, Prof.Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Harald Stefanits, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Universität Wien, Universitätsklinik für Neurochirurgie</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerhard Bavinzski, Prof.Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Gerhard Bavinzski, Prof.Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karl Rössler, Prof.Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dorian Hirschmann, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charité Universitätsmedizin Berlin, Klinik für Neurochirurgie mit Arbeitsbereich pädiatrische Neurochirurgie</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Wolf, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Stefan Wolf, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lars Wessels, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Göttingen, Neurochirurgische Klinik</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dorothee Mielke, Prof.Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Dorothee Mielke, Prof.Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Veit Rohde, Prof.Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Rechts der Isar, Neurochirurgische Klinik und Poliklinik</name>
      <address>
        <city>Munich</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jens Gempt, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Jens Gempt, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Wostrack, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arthur Wagner, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 23, 2020</study_first_submitted>
  <study_first_submitted_qc>February 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 13, 2020</study_first_posted>
  <last_update_submitted>July 8, 2020</last_update_submitted>
  <last_update_submitted_qc>July 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NicaPlant</keyword>
  <keyword>Nicardipine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Subarachnoid Hemorrhage</mesh_term>
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicardipine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

